ライフサイエンスコーパス: multimodal therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ssion to rapid progression despite intensive multimodal therapy.

2 hese men are the most likely to benefit from multimodal therapy.

3 ignancy with a short median survival despite multimodal therapy.

4 tor for poor outcome with current aggressive multimodal therapy.

5 rvival rates less than 40% despite intensive multimodal therapy.

6 have a high likelihood of cure with current multimodal therapy.

7 s and are likely to improve with advances in multimodal therapy.

8 in adults with rhabdomyosarcoma treated with multimodal therapy.

9 -free survival rate in patients who received multimodal therapy.

10 pefully provide more effective, targeted and multimodal therapy.

11 indicator of individual response to evolving multimodal therapies.

12 igh-risk patients are treated with intensive multimodal therapies but cure rates remain suboptimal.

13 gh-risk features; contemporary studies favor multimodal therapy, but high-risk disease is often under

14 Multimodal therapy (chemotherapy, radiation therapy, and

15 Multimodal therapy encompasses a wide range of procedure

16 rature for processes of care and outcomes of multimodal therapies for muscle-invasive urothelial carc

17 Therefore, MGH2 provides effective multimodal therapy for gliomas in preclinical models whe

18 addition, new insights have been gained into multimodal therapy for treating metastatic disease.

19 rm to carry transgenes in order to deliver a multimodal therapy from a single agent.

20 g more effective systemic treatment into the multimodal therapy has been adopted in the CAO/ARO/AIO-0

21 but on assumptions regarding sensitivity to multimodal therapy (i.e., chemotherapy, radiation, intra

22 Multimodal therapy improves cancer-specific outcomes esp

23 We conclude that multimodal therapy including extensive PE was associated

24 enal cell carcinoma should be considered for multimodal therapy, including surgery.

25 Multimodal therapy is composed of chemotherapy and surgi

26 Multimodal therapy is generally more effective than sing

27 , class III clinical trials demonstrate that multimodal therapy is important for both life quality an

28 Alternatively, multimodal therapy is increasingly recognized as a criti

29 Multimodal therapy is increasingly the standard of care

30 Sarcopenia increases through multimodal therapy, is associated with an increased risk

31 oscale drug delivery vehicles can facilitate multimodal therapies of cancer by promoting tumour-selec

32 est incorporation of this agent into initial multimodal therapy of neuroblastoma.

33 All patients undergoing multimodal therapy or surgery with curative intent from

34 Despite multimodal therapy, outcome in rhabdoid tumours remains

35 Despite such aggressive multimodal therapy, prognosis remains poor, with a media

36 ly addition to a waiting list and aggressive multimodal therapy provide excellent results.

37 Patients were treated with risk-directed multimodal therapy regardless of race, ethnicity, or abi

38 nly about one third of patients treated with multimodal therapy remain disease-free, and local contro

39 Despite the use of intensive contemporary multimodal therapy, the overall survival of patients wit

40 he osteoclast and osteoblast compartments as multimodal therapy to prevent SBD.

41 lthough there have been recent advances with multimodal therapy, treatment of neuroblastoma remains a

42 total of 393 consecutive patients completing multimodal therapy were studied, all with prospectively

43 inoma, there is a focus on local control and multimodal therapy with radiation.

44 tandard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk n

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。